Country for PR: United States
Contributor: PR Newswire New York
Wednesday, December 07 2022 - 11:00
Suvoda Launches eCOA-Specific Language and Design Toolkit as Solution Moves to Second Phase of Early Adopter Program
PHILADELPHIA, Dec. 7, 2022 /PRNewswire- AsiaNet/ --

--Practical, innovative functionality seeks to alleviate eCOA burdens, reduce 
time-to-launch, and improve site, clinician, and patient experience.

Suvoda LLC, a global clinical trial technology company that specializes in 
complex studies in therapeutic areas such as oncology, central nervous system 
(CNS), and rare disease, today announced that as part of its single platform 
rollout, its electronic clinical outcome assessments (eCOA) solution is moving 
to the second phase of the Early Adopter program. This solution, designed to 
work seamlessly with Suvoda IRT and eConsent, focuses on tackling the 
historical inefficiencies that continue to plague eCOA, such as gaps in overall 
delivery and execution quality, time consuming translations and localization 
processes, and logistics related to device management.

Logo -

"eCOA is not a new concept, yet the full promise of this eClinical technology 
has yet to be realized by sponsors and CROs, and most importantly, clinical 
trial participants," explains Jill Platko, vice president, scientific services 
at Suvoda. "In support of Suvoda's mission to enhance the clinical trial 
process, Suvoda did not want to simply offer another eCOA solution. But 
instead, wanted to dive into the gaps that make current eCOA implementations so 

Practical Innovations Simplify eCOA Implementations

As it moves into the next phase of the early adopter program, Suvoda's eCOA 
solution incorporates input from its customers and includes reimagined 
processes in four key areas that have proven critical to successful eCOA 

1. Questionnaire Design and Creation

Suvoda eCOA introduces a unique, easy-to-use, configuration-based toolkit 
designed to simplify and accelerate eCOA set-up and delivery. Within it, Suvoda 
offers a proprietary domain-specific language and creation tool that is 
tailor-made for eCOA questionnaires.

An innovative addition to the current eCOA product landscape, this tool 
simplifies eCOA questionnaire creation, accelerates localization, and improves 
access to previews. Questionnaires also can be defined, adjusted, translated, 
validated, and reused across modalities and devices, all in a 
regulatory-compliant environment. This licensing and localization functionality 
includes direct access for translation vendors to further streamline workflows 
and timelines to better meet the needs of any protocol, now and in the future.

2. Device Logistics

Drawing on its 10 years of experience managing the most urgent moments across 
thousands of trials around the world with its IRT solution and support, Suvoda 
is uniquely positioned to set the standard for eCOA device logistics. eCOA 
prioritizes the user experience. With proven processes for clinical trial 
supply chain and data management already in place, Suvoda eCOA will further 
improve real-time data capture and simplify device logistics for global 
clinical trial sites, sponsors, and patients.

3. Real-time Customer Care/Support

With the global capability of its devices and sites, Suvoda supports 
mission-critical issues in real-time — sustaining its reputation of responsive, 
reliable customer care. Congruous with its consistently high client 
satisfaction scores, the company prioritized providing the same level of global 
support excellence for its eCOA customers.

4. Patient Data Integrity through a Single Platform Approach

Suvoda's eCOA, paired with its market-leading IRT solution on a single, 
organically-built platform along with eConsent, ensures a worry-free, 
streamlined approach by reducing the number of integrations required for a 
clinical trial. This transparent integration ensures that patient data will be 
collected and shared seamlessly across the platform, giving users greater 
accessibility to data that is normalized, compliant, unified, and ready for 
analysis. This is a significant advancement that improves data integrity, 
positively impacts trial timelines and output, and creates a more unified user 
experience for patients and site users.

"With a proven track record in services delivery and execution across thousands 
of clinical trials around the world, Suvoda specializes in managing the demands 
of mission-critical, time-sensitive patient interactions," said Suvoda Chief 
Product Officer E.K. Koh. "We are logistics leaders in the clinical trial space 
— and the addition of eCOA to our platform further ensures we are centering the 
patient digital experience without increasing complexity."

Suvoda is still accepting participants in the Early Adopter program as eCOA 
moves into the next phase. Additional enhancements will be released in early 
2023. Click here ( 
) to inquire about becoming an early adopter.

About Suvoda

Suvoda is a global clinical trial technology company that specializes in 
complex, life-sustaining studies in therapeutic areas like oncology, central 
nervous system (CNS), and rare disease. Founded in 2013 by experts in eClinical 
technologies, Suvoda empowers clinical trial professionals to manage the most 
urgent moments in the most urgent trials through advanced software solutions 
delivered on a single platform. Headquartered outside Philadelphia, Suvoda also 
maintains offices in Portland, OR, Barcelona, Spain, Bucharest, Romania and 
Tokyo, Japan. The company consistently boasts a Net Promoter Score (NPS) of 
close to 70, far exceeding the technology industry average of 50, and has been 
selected by trial sponsors and CROs to support more than 1,000 trials across 65 
countries. To learn more, visit ( 
. Follow Suvoda on Twitter ( 
) and LinkedIn ( 

Media Contact: Morgan Reese,